Oncodesign enters into a research collaboration and license agreement with Sanofi for the application of Oncodesign’s Nanocyclix technology to Sanofi’s kinase targets
Oncodesign announced that the company has entered into a strategic research collaboration with Sanofi to apply exclusively Oncodesign’s Nanocyclix(R) technology to several Sanofi kinase target programs. Nanocyclix(R) is a proprietary medicinal chemistry technology and research platform based on macrocyclisation chemical methodology and knowledge that gives access to potent and selective kinase inhibitors based on shape complementarity in the ATP binding site of kinases.
The application of Nanocyclix(R) to Sanofi’s kinase lead programs aims to allow for a quicker selection of development candidates for multiple undisclosed kinase targets in kinase families that are notoriously difficult to address.
Under the terms of the agreement, Oncodesign will exclusively apply its Nanocyclix(R) technology platform in multiple undisclosed Sanofi kinase programs for a number of therapeutic applications over a period of four years. Oncodesign is entitled to a technology access fee and discovery, development, regulatory and commercial milestone payments totaling up to EUR 130 million and low single digit royalties on net sales.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
